Protagonist Therapeutics reported a clean Phase 3 win on Monday for rusfertide — its rare blood disorder therapy — putting it ...
M223, a preclinical drug for inflammatory diseases, with potential milestone payments of $777.5M plus royalties.
Frazier Life Sciences and a cadre of well-known biotech investors are coming together for a new startup in the antibody-drug ...
After Phase 3 depression setback, Neumora pauses two trials to make changes, scraps another
Neumora pauses two Phase 3 trials of navacaprant for depression after earlier trial failure, CEO Paul Berns makes changes to ...
The higher prices of two COPD inhalers from GSK that are targeted in the second round of government drug price negotiations ...
For years, artificial intelligence has been a topic of discussion in pharmaceutical manufacturing, but adoption has been slow ...
Lexicon's non-opioid drug pilavapadin fails Phase 2b pain trial at 20mg dose, but shows promise at 10mg. Company plans Phase ...
Nuvation Bio gets $250M total funding for taletrectinib commercialization & pipeline; Syros to delist from Nasdaq on March 20 after January compliance warning ...
AbbVie becomes an obesity contender as it partners with Danish biotech Gubra in $350M upfront deal for amylin analog GUBamy, ...
Industry groups are looking to push government drug price negotiation and PBM reforms into a massive Republican domestic ...
Biotech investing saw growth in 2024, with RA Capital leading VCs. FDA cancels flu vaccine meeting, Pfizer hires ex-FDA ...
CHMP recommends approval of Regeneron's Lynozyfic, Krystal's Vyjuvek, Accord's trabectedin, Takeda's Deqsiga, and 16 label ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback